|
Treatment/Group
|
Number of Mice
|
Cystitis Disease Score (0 – 4)
|
|---|
|
Control Ab-treated/Naïve
|
15
|
0
|
|
Anti-CXCL10 Ab-treated/Naïve
|
15
|
0
|
|
Control Ab treated/CYP-induced
|
15
|
3.7 ± 0.4*
|
|
Anti-CXCL10 Ab-treated/CYP-induced cystitis
|
15
|
1.6 ± 0.6*,§
|
- The change in urinary bladder inflammation (i.e., cystitis disease score) was evaluated by histopathology. Control or anti-mouse CXCL10 Ab solutions were administered beginning at 2 days prior to CYP (or vehicle alone) treatment and every 2 days thereafter. Five days after CYP (or vehicle alone) administration, mice were sacrificed and urinary bladders were fixed, sectioned at 6 μm, and stained with hematoxylin and eosin. The sections were examined microscopically (at 40× magnification) and scored for the severity of cystitis. The studies were repeated three times, and the data presented are the mean of the cystitis disease score ± standard deviation. Differences between CYP-induced groups and unaffected groups were considered significant when p < 0.01 (*). Differences between control and anti-CXCL10 Ab-treated mice with CYP-induced cystitis were considered significant when p < 0.01 (§).
